Regulation
The regulatory status of research peptides in the US (2026)
In the US, a peptide can be an FDA-approved drug, a substance a pharmacy may compound under certain conditions, or neither. Products labelled “research use only” are in the last group: they are not approved for human use and are not made to pharmaceutical standards. In 2026, federal agencies began revisiting compounding rules for about a dozen popular peptides, but as of our last review the FDA had not issued a final decision.
Key points
- “For research use only” is a sales label. It is not an approval and does not mean a product is safe.
- Compounding pharmacies can only use bulk substances that meet specific legal criteria under section 503A.
- In February 2026 HHS announced plans to move about 14 peptides out of the restricted compounding category.
- In July 2026 an FDA advisory committee voted to recommend six peptides for the 503A bulks list. That vote is non-binding.
Three tiers
| Tier | Examples | What it means |
|---|---|---|
| FDA-approved drug | Semaglutide, tirzepatide, tesamorelin, bremelanotide, elamipretide | Reviewed for safety and efficacy for specific uses; made under good manufacturing practice; prescription only |
| Compoundable substance | Varies with FDA lists and rulings | A licensed pharmacy may prepare it for an individual prescription if the bulk substance meets 503A criteria |
| Research use only | Most peptides in this library | Not approved for human use; no required manufacturing standards; sold for laboratory research |
Compounding categories
For substances nominated before January 2025, the FDA sorted bulk ingredients into categories while it evaluated them. Category 1 substances could be compounded in the interim. Category 2 substances, including BPC-157 from 2023, were flagged as raising significant safety concerns, and pharmacies were expected not to compound them. In January 2025 the FDA changed the framework for new nominations.
What changed in 2026
- February 2026. The Department of Health and Human Services announced that about 14 of the roughly 19 peptides in Category 2 would be moved to Category 1. Reported examples included BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, AOD-9604, GHK-Cu, Selank, Semax, KPV and MOTS-c. Melanotan II, GHRP-2, GHRP-6, LL-37 and PEG-MGF were reported as staying in Category 2.
- July 2026. FDA staff recommended against adding BPC-157, TB-500, KPV and MOTS-c to the 503A bulks list, citing a lack of human clinical data. The Pharmacy Compounding Advisory Committee nevertheless voted to recommend six peptides: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon.
- Current status. Committee votes are advisory. Adding substances to the bulks list requires FDA rulemaking with public comment, which commentators expect to take a year or more. Neither step amounts to FDA approval of any peptide as a drug.
This area is moving quickly. Check the FDA’s compounding pages for the current position.
Sport
The World Anti-Doping Agency prohibits BPC-157 (as a non-approved substance, S0) and growth hormone secretagogues, GHRH analogs and thymosin beta-4 fragments (S2), among others. Athletes are responsible for any prohibited substance in their bodies regardless of how it got there.
Outside the US
Several peptides are approved elsewhere but not in the US: thymosin alpha-1 in a number of countries, Semax and Selank in Russia, mazdutide in China, pralmorelin (GHRP-2) as a diagnostic in Japan. Import rules for personal use differ by country, and many countries treat unapproved injectable peptides as prescription-only medicines or controlled imports.
Related profiles
- Synthetic pentadecapeptide BPC-157 BPC-157 is a synthetic 15-amino-acid peptide studied mainly for tendon, ligament, muscle and gut healing in rodents. Animal studies
- Thymosin beta-4 peptide TB-500 TB-500 is the trade name for synthetic thymosin beta-4 or its active fragment. Early human data
- Mitochondrial-derived peptide MOTS-c MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015. Animal studies
- Anti-inflammatory tripeptide KPV KPV is the C-terminal tripeptide of alpha-MSH and carries much of that hormone’s anti-inflammatory activity without its pigment effects. Animal studies
Questions
Is it legal to buy research peptides?
In the US, selling a substance labelled for research use is not in itself illegal, but marketing it for human use can violate drug law. Rules in other countries differ, and some treat these products as unlicensed medicines.
Does the July 2026 vote mean BPC-157 is approved?
No. It was a non-binding advisory recommendation about compounding, not drug approval. The FDA had not acted on it at our last review.
References
- U.S. Food and Drug Administration (2024). Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding. FDA.
- AJMC staff (2026). 5 things to know about the FDA’s peptide reversal. The American Journal of Managed Care.
- Buchanan Ingersoll & Rooney (2026). FDA Voted Yes on Six Peptides: Now What? The Regulatory Road Ahead. Client alert.